Blood test could predict chronic GVHD after transplant
NCT ID NCT07539220
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at blood samples from 1500 stem cell transplant patients to find markers that can predict chronic graft-versus-host disease (cGVHD), a serious complication. Researchers will use mass spectrometry to analyze proteins in the blood and combine this with patient data to build a prediction model. The goal is to help doctors catch cGVHD earlier, especially when symptoms are hard to spot.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a blood test that helps doctors predict and diagnose chronic GVHD earlier, improving patient care.
- What could go wrong
- This is an observational study, not a treatment trial. The biomarkers identified may not prove accurate in real-world use, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can meditation tame the Long-Term side effects of a stem cell transplant?
- Could a liquid form of a Graft-Versus-Host disease drug be as effective as the pill?
- Scientists map immune battlefield in chronic GVHD tissue
- Could a rheumatoid arthritis drug tame chronic GVHD and cut steroid use?
- Could an arthritis drug tame a tough transplant complication?
- New hope for teens with chronic Graft-Versus-Host disease: belumosudil under study